MTS-conjugated-antiactive caspase 3 antibodies inhibit actinomycin D-induced apoptosis

Area of Science:

• Cell Biology
• Immunology
• Pharmacology

Background:

• Caspase 3 is a critical enzyme in the apoptosis pathway.
• Apoptosis plays a role in various diseases, making its inhibition a therapeutic target.
• Conventional apoptosis inhibitors can have limitations in specificity and toxicity.

Purpose of the Study:

• To develop and evaluate a novel therapeutic strategy for suppressing apoptosis.
• To investigate the efficacy of MTS-transport-peptide conjugated anti-caspase-3 antibodies in inhibiting apoptosis.
• To assess the potential of trans-membrane antibodies as targeted apoptosis inhibitors.

Main Methods:

• Conjugation of MTS-transport-peptide to monoclonal and polyclonal anti-caspase-3 antibodies.
• Treatment of human lymphoma T cells with modified antibodies and Actinomycin D.
• Assessment of apoptosis using DNA ladder electrophoresis and cell death ELISA.

Main Results:

• MTS-transport-peptide modified monoclonal anti-caspase-3 antibody significantly reduced Actinomycin D-induced apoptosis.
• The trans-membrane antibody approach demonstrated specific target recognition within living cells.
• The novel antibody therapy exhibited lower toxicity compared to conventional apoptosis inhibitors.

Conclusions:

• Antibodies conjugated with MTS-transport-peptide are effective in suppressing caspase-3-mediated apoptosis.
• Trans-membrane antibodies offer a targeted and potentially less toxic alternative for apoptosis inhibition.
• This antibody-based strategy holds therapeutic potential for diseases characterized by excessive apoptosis.